NEUP Valuation

Neuphoria Therapeutics Inc

Add to Watchlist

Advanced Chart

9.860

-0.235(-2.328%)1D

Overview
Forecast
Valuation
Earnings

NEUP Relative Valuation

NEUP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, NEUP is overvalued; if below, it's undervalued.

Historical Valuation

Neuphoria Therapeutics Inc (NEUP) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.88. The fair price of Neuphoria Therapeutics Inc (NEUP) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：9.86

Fair

-1.33

Trailing

Forward

-0.09

EV/EBITDA

Neuphoria Therapeutics Inc. (NEUP) has a current EV/EBITDA of -0.09. The 5-year average EV/EBITDA is -0.05. The thresholds are as follows: Strongly Undervalued below -0.44, Undervalued between -0.44 and -0.25, Fairly Valued between 0.14 and -0.25, Overvalued between 0.14 and 0.34, and Strongly Overvalued above 0.34. The current Forward EV/EBITDA of -0.09 falls within the Historic Trend Line -Fairly Valued range.

-0.13

EV/EBIT

Neuphoria Therapeutics Inc. (NEUP) has a current EV/EBIT of -0.13. The 5-year average EV/EBIT is -0.12. The thresholds are as follows: Strongly Undervalued below -0.79, Undervalued between -0.79 and -0.46, Fairly Valued between 0.21 and -0.46, Overvalued between 0.21 and 0.54, and Strongly Overvalued above 0.54. The current Forward EV/EBIT of -0.13 falls within the Historic Trend Line -Fairly Valued range.

0.00

Neuphoria Therapeutics Inc. (NEUP) has a current PS of 0.00. The 5-year average PS is 0.34. The thresholds are as follows: Strongly Undervalued below -1.92, Undervalued between -1.92 and -0.79, Fairly Valued between 1.48 and -0.79, Overvalued between 1.48 and 2.61, and Strongly Overvalued above 2.61. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Neuphoria Therapeutics Inc. (NEUP) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.02. The thresholds are as follows: Strongly Undervalued below -0.15, Undervalued between -0.15 and -0.09, Fairly Valued between 0.05 and -0.09, Overvalued between 0.05 and 0.12, and Strongly Overvalued above 0.12. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Neuphoria Therapeutics Inc. (NEUP) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.04. The thresholds are as follows: Strongly Undervalued below -0.33, Undervalued between -0.33 and -0.18, Fairly Valued between 0.11 and -0.18, Overvalued between 0.11 and 0.26, and Strongly Overvalued above 0.26. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Neuphoria Therapeutics Inc (NEUP) has a current Price-to-Book (P/B) ratio of 0.70. Compared to its 3-year average P/B ratio of 49.66 , the current P/B ratio is approximately -98.58% higher. Relative to its 5-year average P/B ratio of 49.66, the current P/B ratio is about -98.58% higher. Neuphoria Therapeutics Inc (NEUP) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -80.94%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -80.94% , the current FCF yield is about -100.00% lower.

0.70

P/B

Median3y

49.66

Median5y

49.66

3.43

FCF Yield

Median3y

-80.94

Median5y

-80.94

Competitors Valuation Multiple

The average P/S ratio for NEUP's competitors is 0.00, providing a benchmark for relative valuation. Neuphoria Therapeutics Inc Corp (NEUP) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

NEUP.O

Neuphoria Therapeutics Inc

Allarity Therapeutics Inc

Hoth Therapeutics Inc

Loss

25.72M

LEXX.O

Lexaria Bioscience Corp

Loss

107.14%

26.40M

Performance Decomposition

Market capitalization of NEUP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of NEUP in the past 1 year is driven by Unknown.